Genotype-guided tacrolimus dosing in African-American kidney transplant recipients

K. Sanghavi, R. C. Brundage, M. B. Miller, D. P. Schladt, A. K. Israni, W. Guan, W. S. Oetting, R. B. Mannon, R. P. Remmel, A. J. Matas, P. A. Jacobson

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Tacrolimus is dependent on CYP3A5 enzyme for metabolism. Expression of the CYP3A5 enzyme is controlled by several alleles including CYP3A5∗1, CYP3A5∗3, CYP3A5∗6 and CYP3A5∗7. African Americans (AAs) have on average higher tacrolimus dose requirements than Caucasians; however, some have requirements similar to Caucasians. Studies in AAs have primarily evaluated the CYP3A5∗3 variant; however, there are other common nonfunctional variants in AAs (CYP3A5∗6 and CYP3A5∗7) that do not occur in Caucasians. These variants are associated with lower dose requirements and may explain why some AAs are metabolically similar to Caucasians. We created a tacrolimus clearance model in 354 AAs using a development and validation cohort. Time after transplant, steroid and antiviral use, age and CYP3A5∗1, ∗3, ∗6 and ∗7 alleles were significant toward clearance. This study is the first to develop an AA-specific genotype-guided tacrolimus dosing model to personalize therapy.

Original languageEnglish (US)
Pages (from-to)61-68
Number of pages8
JournalPharmacogenomics Journal
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Tacrolimus
African Americans
Genotype
Kidney
Cytochrome P-450 CYP3A
Alleles
Enzymes
Antiviral Agents
Transplant Recipients
Steroids
Transplants

Cite this

Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. / Sanghavi, K.; Brundage, R. C.; Miller, M. B.; Schladt, D. P.; Israni, A. K.; Guan, W.; Oetting, W. S.; Mannon, R. B.; Remmel, R. P.; Matas, A. J.; Jacobson, P. A.

In: Pharmacogenomics Journal, Vol. 17, No. 1, 01.01.2017, p. 61-68.

Research output: Contribution to journalArticle

@article{cda62483def44020aac70b1e91697e7b,
title = "Genotype-guided tacrolimus dosing in African-American kidney transplant recipients",
abstract = "Tacrolimus is dependent on CYP3A5 enzyme for metabolism. Expression of the CYP3A5 enzyme is controlled by several alleles including CYP3A5∗1, CYP3A5∗3, CYP3A5∗6 and CYP3A5∗7. African Americans (AAs) have on average higher tacrolimus dose requirements than Caucasians; however, some have requirements similar to Caucasians. Studies in AAs have primarily evaluated the CYP3A5∗3 variant; however, there are other common nonfunctional variants in AAs (CYP3A5∗6 and CYP3A5∗7) that do not occur in Caucasians. These variants are associated with lower dose requirements and may explain why some AAs are metabolically similar to Caucasians. We created a tacrolimus clearance model in 354 AAs using a development and validation cohort. Time after transplant, steroid and antiviral use, age and CYP3A5∗1, ∗3, ∗6 and ∗7 alleles were significant toward clearance. This study is the first to develop an AA-specific genotype-guided tacrolimus dosing model to personalize therapy.",
author = "K. Sanghavi and Brundage, {R. C.} and Miller, {M. B.} and Schladt, {D. P.} and Israni, {A. K.} and W. Guan and Oetting, {W. S.} and Mannon, {R. B.} and Remmel, {R. P.} and Matas, {A. J.} and Jacobson, {P. A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1038/tpj.2015.87",
language = "English (US)",
volume = "17",
pages = "61--68",
journal = "Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Genotype-guided tacrolimus dosing in African-American kidney transplant recipients

AU - Sanghavi, K.

AU - Brundage, R. C.

AU - Miller, M. B.

AU - Schladt, D. P.

AU - Israni, A. K.

AU - Guan, W.

AU - Oetting, W. S.

AU - Mannon, R. B.

AU - Remmel, R. P.

AU - Matas, A. J.

AU - Jacobson, P. A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Tacrolimus is dependent on CYP3A5 enzyme for metabolism. Expression of the CYP3A5 enzyme is controlled by several alleles including CYP3A5∗1, CYP3A5∗3, CYP3A5∗6 and CYP3A5∗7. African Americans (AAs) have on average higher tacrolimus dose requirements than Caucasians; however, some have requirements similar to Caucasians. Studies in AAs have primarily evaluated the CYP3A5∗3 variant; however, there are other common nonfunctional variants in AAs (CYP3A5∗6 and CYP3A5∗7) that do not occur in Caucasians. These variants are associated with lower dose requirements and may explain why some AAs are metabolically similar to Caucasians. We created a tacrolimus clearance model in 354 AAs using a development and validation cohort. Time after transplant, steroid and antiviral use, age and CYP3A5∗1, ∗3, ∗6 and ∗7 alleles were significant toward clearance. This study is the first to develop an AA-specific genotype-guided tacrolimus dosing model to personalize therapy.

AB - Tacrolimus is dependent on CYP3A5 enzyme for metabolism. Expression of the CYP3A5 enzyme is controlled by several alleles including CYP3A5∗1, CYP3A5∗3, CYP3A5∗6 and CYP3A5∗7. African Americans (AAs) have on average higher tacrolimus dose requirements than Caucasians; however, some have requirements similar to Caucasians. Studies in AAs have primarily evaluated the CYP3A5∗3 variant; however, there are other common nonfunctional variants in AAs (CYP3A5∗6 and CYP3A5∗7) that do not occur in Caucasians. These variants are associated with lower dose requirements and may explain why some AAs are metabolically similar to Caucasians. We created a tacrolimus clearance model in 354 AAs using a development and validation cohort. Time after transplant, steroid and antiviral use, age and CYP3A5∗1, ∗3, ∗6 and ∗7 alleles were significant toward clearance. This study is the first to develop an AA-specific genotype-guided tacrolimus dosing model to personalize therapy.

UR - http://www.scopus.com/inward/record.url?scp=84949870453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949870453&partnerID=8YFLogxK

U2 - 10.1038/tpj.2015.87

DO - 10.1038/tpj.2015.87

M3 - Article

C2 - 26667830

AN - SCOPUS:84949870453

VL - 17

SP - 61

EP - 68

JO - Pharmacogenomics Journal

JF - Pharmacogenomics Journal

SN - 1470-269X

IS - 1

ER -